NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.
Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.
NantHealth's GPS Cancer, which the company began selling in June 2016, integrates quantitative proteomics with whole-genome and transcriptome sequencing data. It provides oncologists with a comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies, including choice of chemotherapy.
"This is a ground-breaking partnership with Oncotest-Teva, and it builds on the growing momentum we've had with payers, providers, and self-insured employers in the United States by bringing GPS Cancer globally," said NantHealth CEO Patrick Soon-Shiong in a statement. "This opportunity to partner with Oncotest-Teva for GPS Cancer truly puts into perspective the depth of our mission — to fight cancer worldwide and to evolve from the era of genomics into the 21st century of quantitative proteomics."
NantHealth also signed an exclusive reseller agreement with Lunatus this week, allowing it to distribute GPS Cancer to physicians in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon.